By Connor Hart
Shares of Fulgent Genetics climbed after the company raised its outlook as it posted higher-than-expected earnings and revenue in the second quarter.
The stock jumped 15%, to $19.75, in premarket trading Friday. Through Thursday's close, shares have lost nearly one-third of their value in the past year.
The company, which runs both laboratory services and therapeutic development businesses, before the bell posted a loss of $19 million, or 62 cents a share, compared with a loss of $8.7 million, or 29 cents a share, a year earlier.
Adjusted earnings came in at 7 cents a share. Analysts surveyed by FactSet had expected an adjusted loss of 18 cents a share.
Revenue rose 15% to $81.8 million, topping the $76.2 million that Wall Street modeled.
For the year, Fulgent raised its revenue guidance by $10 million, to approximately $320 million. The El Monte, Calif., company now expects to post an adjusted loss of about 35 cents a share, compared with a prior outlook of about 65 cents a share.
Analysts are looking for an adjusted loss of 55 cents a share on revenue of $310.7 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
August 01, 2025 09:00 ET (13:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.